Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

A First-in-Human Study of FID-022 in Solid Tumor Patients

NCT07249775 · View on ClinicalTrials.gov ↗

Study Summary

This observational study aims to (1) validate a multimodal artificial intelligence (AI) model for early detection of cancer-associated cachexia in pancreatic cancer patients and (2) assess the feasibility and acceptability of diet and exercise interventions for cachexia management. The study will use retrospective data from the Florida Pancreas Collaborative and prospective data from newly diagnosed patients at Moffitt Cancer Center.

Interventions

  • OTHER Baseline Lifestyle and Symptom Assessment
  • OTHER Extended Lifestyle Monitoring
  • OTHER Feasibility Survey

Study Locations (1)

Florida

  • Moffitt Cancer Center — Tampa

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-10-08
Est. Completion 2026-10

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07249775

The ClinicalTrials.gov registry entry for NCT07249775 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 562 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions — of which Baseline Lifestyle and Symptom Assessment is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07249775 reports 1 study location spanning 1 distinct geographic area — top geographies include Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07249775 about?

NCT07249775 is a clinical study titled "A First-in-Human Study of FID-022 in Solid Tumor Patients". This observational study aims to (1) validate a multimodal artificial intelligence (AI) model for early detection of cancer-associated cachexia in pancreatic cancer patients and (2) assess the feasibility and acceptability of diet and exercise interventions for cachexia management. The study will us...

What is the current status of trial NCT07249775?

This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2025-10-08. Estimated completion is 2026-10.

What conditions does trial NCT07249775 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Cancer Cachexia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07249775?

The interventions under investigation include: Baseline Lifestyle and Symptom Assessment (OTHER), Extended Lifestyle Monitoring (OTHER), Feasibility Survey (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07249775?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 562 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07249775 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial